Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of MRG003 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• MRG003

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: RECRUITING